ET Capital

ET Capital, established in 1992, is a distinguished venture capital firm based in southern England, with a particular focus on the dynamic tech ecosystems around Cambridge, Oxford, and London. The firm has raised and managed a series of funds aimed at high-growth technology businesses within these globally significant clusters. Initially backed by HSBC and the European Investment Fund, ET Capital has since evolved into a key player in the UK’s venture capital landscape, particularly in the realms of life sciences, information technology, and green technology. The firm has a robust portfolio of over 40 companies, with notable successes like ADC Therapeutics, a biotech company that went public on the NYSE in 2020 with a valuation of $1.3 billion. ET Capital also plays a pivotal role in the climate tech space through its management of the Carbon13 SEIS Funds, which invest in startups dedicated to addressing the climate emergency. These funds are closely linked to the Carbon13 venture builder, a Cambridge-based initiative that fosters innovative companies focused on significant carbon emission reductions. Led by Managing Director Martin Rigby, who brings over 30 years of experience in early-stage technology investments, ET Capital is known for its deep expertise in nurturing innovative tech companies from inception to success. The firm’s investment strategy is characterized by a strong emphasis on early-stage, science-based businesses with the potential to scale globally. ET Capital’s partnerships extend internationally, including ventures like the UK China Enterprise, which supports science-based businesses aiming to expand into the Chinese market​.